Spinal fluid test distinguished MS from similar diseases
By MS Buddy ·
Summarized from Cell, Apr 2026 · PubMed. AI-generated summary. Not medical advice.
Observational study · 5,000 people with MS and other neurological disorders
Research by Jakob Maximilian Bader, Matthias Mann and 17 colleagues at Max Planck Institute of Biochemistry, the Technical University of Munich and 2 other institutions in Germany and Denmark.
Can a spinal fluid test tell MS from similar inflammatory diseases?
Key Takeaway
A new spinal fluid test distinguished MS from related inflammatory diseases, including challenging cases.

What They Found
Researchers measured proteins in spinal fluid from people with a range of neurological disorders. They found changes linked to age, sex, and how well the barrier between blood and spinal fluid was working. In MS, a group of 22 proteins distinguished it from related inflammatory diseases. The group performed better than established markers in challenging cases and was confirmed in a separate group. Protein patterns also helped place people along a range from relapsing to progressive MS and were linked to clinical outcomes.
Who Should Care and Why
The study included people with MS and people with other neurological disorders. It focused on whether spinal fluid could help tell MS apart from similar inflammatory diseases. That question matters when a diagnosis is hard to make. Researchers also studied how protein patterns differed across relapsing and progressive MS. The findings concern a lab test, not a treatment.
Important Considerations
You should know this was a study of spinal fluid samples from 5,000 people, not a treatment trial. The abstract does not say how many people had MS or give the test's exact accuracy. It does not show whether using the test improves care for you.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Cell by et al.. Reproduced from the PubMed record.
Cerebrospinal fluid (CSF) is central to neurological diagnostics, yet biomarkers are lacking for many clinical needs. To enable its large-scale proteomic characterization, we developed a high-throughput mass spectrometry workflow quantifying approximately 1,500 proteins per CSF sample across 5,000 individuals, covering a spectrum of neurological disorders. This revealed proteomic alterations associated with blood-CSF barrier impairment, age, and sex, enabling deconvolution of shared and disease-specific signatures. We then focused on multiple sclerosis (MS), using an improved analytical technology that quantified 2,100 proteins per sample. From these data, we derived a 22-protein panel that distinguished MS from related inflammatory diseases and outperformed established markers in challenging cases. A targeted mass spectrometry assay using isotope-labeled standards validated this panel in an independent cohort, offering a clinically compatible format. Additionally, we highlight proteins of therapeutic interest and demonstrate proteome-based staging of individuals along the relapsing-progressive MS spectrum, which correlates with clinical outcomes.
Categories
Explore more research
Related MS research

11/20/2026
In a study of 140 people, a spinal fluid test better separated MS from other nervous system conditio
Read More
11/20/2026
In people with MS, brain scan readings were stronger when images lined up with the scanner’s magneti
Read More
11/20/2026
A study of 59 people with relapsing-remitting MS found a computer tool helped doctors read brain sca
Read More
11/19/2026
A Japanese hospital study linked MS to about 9% of first eye nerve inflammation cases. Other immune
Read More
11/18/2026
An adjusted MRI scan found more veins within MS brain lesions in 17 people with MS. It improved scan
Read More
11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
